Simon C.H. Yu, Simon S.M. Ho, Wan Y. Lau, Deacons T.K. Yeung, Edmund H.Y. Yuen, Paul S.F. Lee, Constantine Metreweli – 25 March 2004 – This study aims to compare the therapeutic effectiveness of continuous catheter drainage versus intermittent needle aspiration in the percutaneous treatment of pyogenic liver abscesses.
Vlad Ratziu, Françoise Imbert‐Bismut, Djamila Messous, Thierry Poynard – 25 March 2004
Leon A. Adams, Ariel Feldstein, Keith D. Lindor, Paul Angulo – 25 March 2004 – Patients with hypopituitarism develop a phenotype similar to metabolic syndrome with central obesity and diabetes. Similarly, patients with hypothalamic damage may develop central obesity, insulin resistance, and hyperphagia. We sought to examine the clinical associations between hypopituitarism, hypothalamic dysfunction, and nonalcoholic fatty liver disease (NAFLD).
Yung‐Chang Chen, Pere Ginès, Jianhui Yang, Sandra N. Summer, Sandor Falk, Nash S. Russell, Robert W. Schrier – 25 March 2004 – Vascular heme oxygenase (HO) regulates vascular tone in normal conditions and in some pathologic circumstances (e.g., sepsis). However, its possible role in the pathogenesis of arterial vasodilation in cirrhosis is unknown. To address this question, the expression and activity of HO in arterial vessels was studied in rats at 1, 2, and 4 weeks after bile duct ligation (BDL) or sham operation.
Ian P.J. Alwayn, Patrick J. Javid, Kathleen M. Gura, Vânia Nosé, Mario Ollero, Mark Puder – 25 March 2004
Manuel Romero‐Gómez, Lourdes Grande, Inés Camacho – 25 March 2004 – Oral glutamine challenge (OGC) has been found to be safe, and an altered response predicts elevated risk of overt hepatic encephalopathy (HE) in patients with minimal hepatic encephalopathy (MHE). We assessed the survival prognosis of patients with cirrhosis, but without current overt HE, who have an altered OGC and MHE. MHE was inferred using 3 neuropsychological tests. Venous ammonia concentrations were measured pre‐ and post‐60 minutes of a 10 g oral glutamine load.
Arun J Sanyal – 25 March 2004
J. Michael Millis – 22 March 2004
Kellee Slater, Thomas E. Bak, Igal Kam, Michael E. Wachs – 22 March 2004 – Liver transplantation is now an acceptable treatment for small hepatocellular carcinomas in the setting of cirrhosis. Larger tumors in cirrhotic livers and unresectable tumors in noncirrhotic livers (including fibrolamellar hepatocellular carcinomas) may also be indications for transplantation. With the limited number of cadaver grafts available, living donor liver transplant is becoming an option for some of these patients.